Related Experiment Video
Updated: Jun 29, 2025

06:19
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
807
Improved Glaucoma Medication Access Through Pharmacy Partnership: A Single Institution Experience.
Jin G Choi1,2, Pathik Amin3, Alaina Tarantino4
1Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Clinical Ophthalmology (Auckland, N.Z.)
|April 8, 2024
Summary
High out-of-pocket costs hinder glaucoma medication adherence. A University of Chicago Medical Center (UCMC) pilot program revealed most medication inquiries faced coverage denials or high costs, impacting patient access and adherence.
Area of Science:
- Ophthalmology
- Health Services Research
- Pharmacoeconomics
Background:
- Patient out-of-pocket costs are a significant barrier to glaucoma medication adherence.
- The University of Chicago Medical Center (UCMC) implemented a pilot program to assess medication costs based on insurance coverage.
Purpose of the Study:
- To evaluate the impact of a collaboration between the glaucoma service and outpatient pharmacy.
- To analyze the effect of a pharmacy-led cost inquiry program on glaucoma medication access.
Main Methods:
- Retrospective chart review of glaucoma patients undergoing formulary inquiries.
- Analysis of medication changes, access barriers (prior authorizations, exceptions), and out-of-pocket costs.
- Inquiry period: April 1, 2020, to February 28, 2022, at a single institution.
Main Results:
- 343 formulary inquiries (568 medication inquiries) were analyzed.
- Only 78 (13.7%) medications were affordable without additional steps.
- 445 (78.3%) inquiries resulted in denials or prohibitive costs, even after additional steps.
Conclusions:
- The UCMC workflow improved transparency of out-of-pocket medication costs for glaucoma patients.
- This collaborative model may reduce system burden by improving prescription fulfillment rates.
- Implementing similar physician-pharmacy workflows can mitigate costs and enhance patient care quality.
Related Concept Videos
Open Angle Glaucoma: Treatment
440
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
440
Glaucoma: Overview
560
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
560
Angle Closure Glaucoma: Treatment
485
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
485

